CD8A and cancer: VISTA blocker inhibits interaction of VISTA on cancer with VISTA on immune cells, as well as with other VISTA receptors; Promotes anti-cancer effector functions of immune cells; inhibits cancer stem cell survival and cancer progression; Reduces Tregs through ADCC; Increases progenitor and memory-like CD8+ T cells; Enhances anti-cancer vaccine responses